Conavi Medical Corp. has achieved a significant milestone with the FDA 510(k) clearance for its next-generation hybrid imaging system, which integrates intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single platform. This innovative system allows for simultaneous, co-registered imaging of coronary arteries, enhancing the visualization of both deep vessel structures and high-resolution surface details. The company is set to launch this technology commercially in the U.S. in the second half of 2026, positioning itself to capitalize on a burgeoning intravascular imaging market estimated to exceed $4 billion annually.

The hybrid IVUS-OCT system addresses a critical gap in the current intravascular imaging landscape, where the complexity of using multiple systems has hindered wider adoption. By enabling a comprehensive assessment of coronary anatomy within a single workflow, this technology can significantly improve physician decision-making during percutaneous coronary interventions (PCI). Dr. Megha Prasad, an interventional cardiologist, highlighted its potential to enhance procedural efficiency by allowing simultaneous evaluation of plaque composition, vessel size, and stent expansion, thus supporting better outcomes for patients.

The introduction of Conavi’s hybrid imaging system marks a pivotal shift in the field of interventional cardiology, as it streamlines workflows and enhances the precision of image-guided care. This advancement not only has the potential to improve clinical outcomes but also aligns with the increasing focus on optimizing stent placement and reducing the need for repeat interventions. As healthcare systems prioritize efficiency and precision, the success of this technology could catalyze further innovations in intravascular imaging, ultimately reshaping current research paradigms and influencing future drug development timelines.

Source: globenewswire.com